Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
Total raised: $137M
Investors 5
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
| - | T1D Fund | t1dfund.or... |
| - | Forbion | forbion.co... |
| - | Genesys Ca... | genesyscap... |
| - | Anges Québ... | angesquebe... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.10.2022 | Series C | $95M | - |
| 08.09.2020 | Series B | $35M | Forbion |
| 25.07.2018 | Series A | $7M | - |
Mentions in press and media 16
| Date | Title | Description |
| 13.06.2025 | The Rise of Canadian Life Sciences: A New Era of Innovation and Investment | In the heart of Canada, a revolution is brewing. The life sciences sector is experiencing a surge, fueled by innovative companies and strategic investments. Two recent announcements highlight this trend: Genesys Capital's closing of its lar... |
| 11.06.2025 | Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP | TORONTO & MONTREAL–(BUSINESS WIRE)–June 11, 2025– Genesys Capital (“Genesys”) is pleased to announce the upcoming closing of Genesys Ventures IV LP (“Fund IV” or the “fund”) to continue its successful track record of building Canadian l... |
| 31.05.2024 | Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation | The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I • This is Forbion's sixth consecutive... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 17.11.2022 | Forbion Portfolio Company Inversago named in Labiotech list of "The hottest private biotech companies in Canada" | The hottest private biotech companies in Canada BY JONATHAN SMITH NOVEMBER 17, 2022 |
| 17.10.2022 | Inversago Pharma Raises $95 million CAD in Series C Financing | MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 mi... |
| 17.10.2022 | Inversago Pharma Raises CAD$95M in Series C Financing | Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C funding. The round was led by New Enterprise Associates, with participation from Forbion’s Growth, Amgen Ventures, Forbion Ventures, Fonds ... |
| 17.01.2022 | Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update | MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder ... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors | Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité... |
Show more